Novartis: UBS lowers its price target


(CercleFinance.com) – The analyst has low confidence in the group’s growth aspirations. He confirms his neutral advice on the value and lowers his target price to 80 CHF (from 86 CHF).

“We have reviewed our investment thesis with a focus on innovative medicines, but we are not confident enough in its growth prospects to warrant a reassessment,” UBS said.

Vas Narasimhan, its managing director, said the laboratory is aiming for an average annual growth in turnover of around 4% by 2027.

Its ‘core’ operating margin should stand at a level greater than or equal to 40% over the medium and long term.

Novartis – which now says it wants to focus on five main areas of activity (cardiovascular, immunology, neurosciences, solid tumors and hematology) – explains that it intends above all to concentrate its development on the American market, but also on countries such as China, Germany and Japan.

Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85